This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| European Network of Centres for Pharmacoepidemiology and Pharmacovigilance | |
|---|---|
| Name | European Network of Centres for Pharmacoepidemiology and Pharmacovigilance |
| Abbreviation | ENCePP |
| Formation | 2006 |
| Type | Network |
| Headquarters | London |
| Region served | European Union |
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance is a European medicines initiative that coordinates research on medicine safety and effectiveness across multiple European Union member states, linking academic centres, regulatory authorities, and pharmaceutical industry stakeholders. It was created to strengthen post‑marketing surveillance by integrating resources from institutions such as the European Medicines Agency, national competent authorities like Agence nationale de sécurité du médicament et des produits de santé, and academic partners including University of Utrecht and London School of Hygiene and Tropical Medicine. The network interfaces with legislative frameworks from the European Parliament and programmatic structures originating in European Commission initiatives.
The network was established in 2006 following policy work by the European Medicines Agency and consultations involving the European Commission Directorate‑General for Health and Food Safety, representatives from the European Parliament, and national regulators such as Medicines and Healthcare products Regulatory Agency and Bundesinstitut für Arzneimittel und Medizinprodukte. Early drivers included pharmacovigilance reforms after high‑profile safety issues associated with products reviewed under procedures in the European Medicines Agency and mandates arising from directives debated at the Council of the European Union. Founding participants drew on experience from projects funded by Framework Programme 6 and collaborations with academic centres like Karolinska Institutet and Université Paris Descartes.
ENCePP operates as a distributed network composed of academic centres, research organizations, regulatory bodies, and private sector partners from countries across the European Economic Area, including members from Norway, Iceland, and Switzerland. Membership encompasses institutions such as University of Barcelona, Università degli Studi di Milano, Charité – Universitätsmedizin Berlin, and national agencies like Agence nationale de sécurité du médicament et des produits de santé and Conseil supérieur de la santé (Belgium). The network maintains a public register and a database that catalogs participating centres and leads, with governance interactions involving entities such as European Observatory on Health Systems and Policies and advisory input from professional societies including International Society for Pharmacoepidemiology.
Primary objectives include improving post‑marketing safety surveillance, facilitating multi‑database pharmacoepidemiological studies, and promoting methodological standards across participating centres. Activities range from coordinating large observational studies engaging partners such as Aarhus University, Erasmus University Rotterdam, and Ghent University to providing guidance documents and quality checklists used by regulators like Medicines and Healthcare products Regulatory Agency and policy‑makers in the European Commission. The network also sponsors methodological workshops involving stakeholders from World Health Organization, Organisation for Economic Co‑operation and Development, and professional bodies such as European Society of Clinical Pharmacy.
Governance arrangements involve steering committees and an executive secretariat that liaises with the European Medicines Agency and member institutions including University of Utrecht and London School of Hygiene and Tropical Medicine. Funding streams have included grants from the European Commission research frameworks (e.g., Seventh Framework Programme for Research and Technological Development), project‑specific contracts with national authorities like Agence nationale de sécurité du médicament et des produits de santé, and collaborations with industry partners such as multinational companies headquartered in Basel and Brussels. Financial oversight has been subject to scrutiny by auditors and discussed in forums including European Court of Auditors briefings and European Parliament committee hearings.
ENCePP has promoted standardized protocols, common data models, and transparency measures adopted in multicentre studies undertaken with universities such as University of Copenhagen, University of Helsinki, and University of Manchester. Methodological outputs include guidance on confounding control, database interoperability influenced by initiatives from Agence Française de Sécurité Sanitaire des Produits de Santé and data harmonization efforts aligned with projects involving Observational Health Data Sciences and Informatics partners. The network has supported pharmacoepidemiological work on vaccines and therapeutics, engaging disease‑focused centres like Robert Koch Institute and collaborators at Instituto de Salud Carlos III.
Collaborative links extend to the European Medicines Agency, national competent authorities (e.g., Zorginstituut Nederland), academic consortia such as European Clinical Research Infrastructure Network, and international organizations including World Health Organization and Organisation for Economic Co‑operation and Development. Partnerships with registries and databases involve institutions like Danish Health Data Authority, National Institute for Health and Care Research, and the Finnish Institute for Health and Welfare. ENCePP has participated in joint activities with industry consortia, patient organizations including European Patients' Forum, and methodological groups such as the International Society for Pharmacoepidemiology.
Supporters credit the network with strengthening regulatory science, improving transparency in post‑marketing research, and enabling multicountry studies that informed decisions by bodies such as the European Medicines Agency and national ministries like Ministry of Health (France). Criticisms have focused on potential conflicts of interest when industry funding is involved, the variable quality of participating databases including concerns raised by researchers at Karolinska Institutet and University of Oxford, and the adequacy of enforcement mechanisms compared with recommendations from panels convened by the European Parliament and auditor reports by the European Court of Auditors. Debates continue regarding balance among stakeholders represented by institutions such as European Federation of Pharmaceutical Industries and Associations and patient advocacy groups like European Patients' Forum.
Category:Pharmacoepidemiology Category:Pharmacovigilance Category:European Union health organizations